biotech · Major Depressive Disorder · Alzheimer's Disease · NMRA
Neumora Therapeutics
Neumora Therapeutics patent portfolio — 6 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- copenhagen, DK
- Employees
- 18
- Programs
- 5
- Drugs
- 2
- Patents
- 6
Neumora Therapeutics patents
6 pharmaceutical patents indexed for Neumora Therapeutics. 0 expire within 24 months.
Neumora Therapeutics has 6 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12371414
Methods of treating neurological disorders
granted -
US 12247037
1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders
granted -
US 12171758
Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto
granted -
US 12152038
Vasopressin receptor antagonists and products and methods related thereto
granted -
US 11993580
Methods of treating neurological disorders
granted -
US 11858943
Vasopressin receptor antagonists and products and methods related thereto
granted
Frequently asked questions
How many patents does Neumora Therapeutics have?
6 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Neumora Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.